UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause of bacterial pneumonia for them. Indeed, it was the most frequently isolated ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

The partnership integrates Leveragen’s Singularity Sapiens Mouse platform with the T-cell engineering expertise of Moonlight ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Acquisition to strengthen key pillar of BioNTech's oncology strategy aimed at establishing BNT327 as a pan-tumor technology platform for the treatment of advanced cancersWith the closing of the transa ...

The Global Oncology Drug market was estimated at $227.2 billion in 2024 and is projected to reach $582.21 billion by 2034 , reflecting a robust CAGR of 11.67% over the forecast period from 2024 to ...

Measurements of antidrug antibodies are essential for rational ... Infliximab/Remicade® (Janssen Biotech Inc., PA, USA) is a chimeric mAb composed of a constant human IgG1-κ-chain spliced ...